Why the Drug Delivery Industry Can Consolidate
Drug delivery companies have been consolidating with a fury over the last twelve months, unlike biotechs. The difference: delivery firms have plenty of drug service companies to sell to (other drug delivery firms, distributors, generic houses), while biotechs can only sell to Big Pharma--which doesn't want to buy them.
You may also be interested in...
Pink Sheet reporters and editors dig into the emerging coronavirus vaccine regulatory schedule, look at vaccine purchasing trends, and consider the curious case of a federal government billboard encouraging convalescent plasma donations.
Siemens Healthineers' acquisition of radiation oncology company Varian Medical Systems creates an oncology giant. Analysts disagree on whether its the right move for the companies.
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.